Location History:
- Roemerberg, FR (2019)
- Wolfersdorf, DE (2012 - 2020)
- Roemerberg, DE (2020 - 2023)
Company Filing History:
7 out of 36 
4 out of 16 
1 out of 832,680 Years Active: 2012-2023
Title: **Martin Huelsmeyer: Pioneering Innovations in Lipocalin Muteins**
Introduction
Martin Huelsmeyer, an accomplished inventor based in Wolfersdorf, Germany, has made significant contributions to the field of biotechnology through his innovative work. With a portfolio of 12 patents, he focuses on the development of therapeutic and diagnostic proteins, particularly those related to human lipocalin 2.
Latest Patents
Huelsmeyer’s latest patents delve into the area of muteins derived from human lipocalin 2 (Lcn2, hNGAL). One notable invention pertains to a novel library designed for generating muteins that possess an affinity for a specific target. This invention not only introduces new muteins but also outlines the corresponding nucleic acid molecules and methodologies for their generation. These novel muteins have potential applications in binding and depleting pathological forms of biomolecules, such as the amyloid beta peptide linked to Alzheimer’s disease, and targeting fibronectin extra-domain B associated with tumor neovasculature.
Another significant patent discloses the creation of proteins that specifically bind to Glypican-3 (GPC3), highlighting therapeutic or diagnostic uses. This innovation further comprises nucleic acid molecules encoding such proteins and methodologies for their application, suggesting promising advancements in pharmaceutical and diagnostic compositions.
Career Highlights
Throughout his career, Martin Huelsmeyer has been associated with commendable organizations including Pieris Pharmaceuticals GmbH and Pieris AG. His work has bridged gaps in understanding and utilizing lipocalins for medical advancements, contributing to the development of innovative therapies.
Collaborations
In his pursuit of innovation, Huelsmeyer has collaborated with notable individuals in the field, including Gabriele Matschiner and Arne Skerra. These partnerships underline the importance of teamwork in driving advancements in biotechnological research and product development.
Conclusion
Martin Huelsmeyer stands out as a significant figure in the realm of biotechnology, particularly through his focused work on lipocalin muteins. His patents not only highlight innovative approaches to therapeutic and diagnostic applications but also reflect a commitment to advancing medical science. As research progresses, Huelsmeyer’s inventions may pave the way for groundbreaking treatments in various diseases, showcasing the profound impact of his contributions to the field.
Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.